Tasosartan

Tasosartan
Systematic (IUPAC) name
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
Clinical data
Pregnancy
category
  • N/A
Legal status
  • Withdrawn
Identifiers
CAS Number 145733-36-4 YesY
ATC code C09CA05
PubChem CID 60919
IUPHAR/BPS 6898
DrugBank DB01349 YesY
ChemSpider 54890 N
UNII 48G92V856H YesY
Chemical data
Formula C23H21N7O
Molar mass 411.459 g/mol
 NYesY (what is this?)  (verify)

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]

References

  1. ↑ Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
  2. ↑ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm 57 (13): 1231–41. PMID 10902066.



This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.